Sarsha Yap , Anna Kelly , David Goldsbury , Marianne F. Weber , Xue Qin Yu , Qingwei Luo , Karen Canfell , Eleonora Feletto
{"title":"Health system costs and autologous stem cell transplant receipt for participants with multiple myeloma in the Australian 45 and Up Study","authors":"Sarsha Yap , Anna Kelly , David Goldsbury , Marianne F. Weber , Xue Qin Yu , Qingwei Luo , Karen Canfell , Eleonora Feletto","doi":"10.1016/j.leukres.2025.108100","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In Australia, the number of people living with multiple myeloma (MM) is projected to increase. We examined the health system costs and autologous stem cell transplant (ASCT) receipt among participants with MM diagnosed between 2006 and 2019 from the Australian 45 and Up Study cohort (267,357 participants).</div></div><div><h3>Materials and methods</h3><div>We identified 520 participants diagnosed with MM using cancer registry records. Direct excess health system costs were calculated by subtracting the mean values observed for 2533 matched participants without cancer from those observed for participants with MM. Costs were calculated from 2 years pre-diagnosis up to 5 years post-diagnosis, for different phases of care and at end of life. Participant characteristics associated with health system costs were analysed using gamma regression. Characteristics associated with ASCT receipt were analysed using competing risks regression.</div></div><div><h3>Results</h3><div>Mean excess health system cost per person was $8846 in the year pre-diagnosis and peaked at $66,249 in the year post-diagnosis. From 2- to 5-years post-diagnosis, mean excess costs per person ranged between $36,453 and $43,059 and remained substantially higher than pre-diagnosis levels. Within the 5-years post-diagnosis, 125 (24.0 %) received ASCT. Older age at diagnosis was strongly associated with lower costs (each one-year increase, relative rate (RR)= 0.97, 95 % CI:0.96–0.98 for initial phase of care costs) and a lower rate of ASCT (each one-year increase, sub-hazard ratio (SHR)= 0.85, 95 % CI:0.83–0.87).</div></div><div><h3>Conclusions</h3><div>Health system costs for individuals with MM were significantly higher post-diagnosis than pre-diagnosis and remained elevated for at least 5-years. This work provides insights for future healthcare requirements for MM.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"158 ","pages":"Article 108100"},"PeriodicalIF":2.2000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia research","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0145212625005909","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
In Australia, the number of people living with multiple myeloma (MM) is projected to increase. We examined the health system costs and autologous stem cell transplant (ASCT) receipt among participants with MM diagnosed between 2006 and 2019 from the Australian 45 and Up Study cohort (267,357 participants).
Materials and methods
We identified 520 participants diagnosed with MM using cancer registry records. Direct excess health system costs were calculated by subtracting the mean values observed for 2533 matched participants without cancer from those observed for participants with MM. Costs were calculated from 2 years pre-diagnosis up to 5 years post-diagnosis, for different phases of care and at end of life. Participant characteristics associated with health system costs were analysed using gamma regression. Characteristics associated with ASCT receipt were analysed using competing risks regression.
Results
Mean excess health system cost per person was $8846 in the year pre-diagnosis and peaked at $66,249 in the year post-diagnosis. From 2- to 5-years post-diagnosis, mean excess costs per person ranged between $36,453 and $43,059 and remained substantially higher than pre-diagnosis levels. Within the 5-years post-diagnosis, 125 (24.0 %) received ASCT. Older age at diagnosis was strongly associated with lower costs (each one-year increase, relative rate (RR)= 0.97, 95 % CI:0.96–0.98 for initial phase of care costs) and a lower rate of ASCT (each one-year increase, sub-hazard ratio (SHR)= 0.85, 95 % CI:0.83–0.87).
Conclusions
Health system costs for individuals with MM were significantly higher post-diagnosis than pre-diagnosis and remained elevated for at least 5-years. This work provides insights for future healthcare requirements for MM.
期刊介绍:
Leukemia Research an international journal which brings comprehensive and current information to all health care professionals involved in basic and applied clinical research in hematological malignancies. The editors encourage the submission of articles relevant to hematological malignancies. The Journal scope includes reporting studies of cellular and molecular biology, genetics, immunology, epidemiology, clinical evaluation, and therapy of these diseases.